The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net loss | -1,850,493 | -1,981,293 | -15,941,328 |
| Amortization of debt discount | 2,021,209 | - | - |
| Loss on extinguishment of debt | 0 | -364,109 | - |
| Change in fair value of derivative liabilities | 775,062 | -289,401 | -94,917 |
| Interest expense | - | 527,893 | 289,931 |
| Stock based compensation | 0 | 0 | 14,131,250 |
| Prepaid expenses | -363,768 | 164,218 | 389,615 |
| Inventory | 35,437 | - | - |
| Due from related party | - | 0 | 1,027,920 |
| Accounts payable | -1,318,670 | -80,386 | 1,121,806 |
| Accrued expenses | 280,780 | -95,816 | 80,457 |
| Other current liabilities | 0 | 0 | -111,026 |
| Net cash flows provided by (used in) operating activities | -1,103,809 | -1,140,310 | -1,751,528 |
| Issuance of common stock | - | 0 | 0 |
| Proceeds from recapitalization | -1 | 0 | 265,828 |
| Proceeds from issuance of convertible notes | 7,250,000 | 0 | 3,000,000 |
| Repayment of convertible notes | 3,032,645 | - | - |
| Repayment of subscription agreement loan | 483,474 | - | - |
| Transaction costs paid in connection with convertible notes | 907,499 | - | - |
| Proceeds from notes payable - related party | 0 | 0 | 50,000 |
| Repayment of notes payable related party | -19,466 | 0 | 221,390 |
| Net cash flows provided by (used in) financing activities | 2,845,847 | 0 | 3,094,438 |
| Net change in cash | 1,742,038 | -1,140,310 | 1,342,910 |
| Cash and cash equivalents at beginning of period | 3,633 | - | - |
| Cash and cash equivalents at end of period | 1,948,271 | - | - |
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)